EP0616525A1 - Medicaments. - Google Patents

Medicaments.

Info

Publication number
EP0616525A1
EP0616525A1 EP92924669A EP92924669A EP0616525A1 EP 0616525 A1 EP0616525 A1 EP 0616525A1 EP 92924669 A EP92924669 A EP 92924669A EP 92924669 A EP92924669 A EP 92924669A EP 0616525 A1 EP0616525 A1 EP 0616525A1
Authority
EP
European Patent Office
Prior art keywords
formulation
medicament
propellant
particulate
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92924669A
Other languages
German (de)
French (fr)
Other versions
EP0616525B1 (en
Inventor
Rachel Ann Akehurst
Anthony James Taylor
David Andrew Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26299998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0616525(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919126444A external-priority patent/GB9126444D0/en
Priority claimed from GB929202522A external-priority patent/GB9202522D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP0616525A1 publication Critical patent/EP0616525A1/en
Application granted granted Critical
Publication of EP0616525B1 publication Critical patent/EP0616525B1/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to aerosol formulations of use for the administration of medicaments by inhalation.
  • aerosols to administer medicaments has been known for several decades.
  • Such aerosols generally comprise the medicament, one or more chlorofluorocarbon propellants and either a surfactant or a solvent, such as ethanol.
  • the most commonly used aerosol propellants for medicaments have been propellant 1 1 (CC1,F) and/or propellant 1 14 (CF,C1CF,C1) with propellant 12 (CC1 2 F,).
  • propellants are now believed to provoke the degradation of stratospheric ozone and there is thus a need to provide aerosol formulations for medicaments which employ so called "ozonevfriendly" propellants.
  • a class of propellants which are believed to have minimal ozone-depleting effects in comparison to conventional chlorofluorocarbons comprise, fluorocarbons and hydrogen-containing chlorofluorocarbons, and a number of medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777, WO91/04011, WO91/11 173, WO91/11495 and WO91/14422.
  • These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome the problems associated with the use of the new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared.
  • the applications all propose the addition of one or more of adjuvants such as alcohols, alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids, polyethoxylates etc) and even conventional chlorofluorocarbon propellants in small amounts intended to minimise potential ozone damage.
  • adjuvants such as alcohols, alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids, polyethoxylates etc) and even conventional chlorofluorocarbon propellants in small amounts intended to minimise potential ozone damage.
  • EP 0372777 requires the use of 1, 1, 1,2-tetrafluoroethane in combination with both a cosolvent having greater polarity than 1, 1, 1,2-tetrafluoroethane (e.g. an alcohol or a lower alkane) and a surfactant in order to achieve a stable formulation of.a medicament powder.
  • a cosolvent having greater polarity than 1, 1, 1,2-tetrafluoroethane e.g. an alcohol or a lower alkane
  • a surfactant in order to achieve a stable formulation of.a medicament powder.
  • Surfactants are generally recognised by those skilled in the art to be essential components of aerosol formulations, required not only to reduce aggregation of the medicament but also to lubricate the valve employed, thereby ensuring consistent reproducibil ⁇ ty of valve actuation and accuracy of dose dispensed.
  • WO91/11173, WO91/11495 and WO91/14422 are concerned .with formulations comprising an admixture of drug and surfactant
  • WO91/04011 discloses medicinal aerosol formulations in which the particulate medicaments are pre-coated with -surfactant prior to dispersal in 1,1,1,2-tetrafluoroethane.
  • a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon • or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon * propellant of a polar cosolvent, which formulation is substantially free of surfactant.
  • substantially free of surfactant is meant formulations which contain no significant amounts of surfactant, for example less than 0.0001% by weight of the medicament. .
  • the particle size of the particulate (e.g. micronised) medicament should be such as to permit inhalation of substantially all of the medicament into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and preferably in the range 1-10 microns, e.g. 1-5 microns.
  • Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant.
  • Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, - dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; anti-infectives, e.g.
  • cephalosporins e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine
  • antihistamines e.g. methapyrilene
  • anti-inflammatories e.g. beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone
  • antitussives e.g. noscapine
  • bronchodilators e.g.
  • ephedrine adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, isoetharine, tulobuterol, orciprenaline, or (-)-4-amino-3,5-dichloro- ⁇ -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzene- methanol; diuretics, e.g. amiloride; anticholinergics e.g.
  • the medicaments may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.
  • salts e.g. as alkali metal or amine salts or as acid addition salts
  • esters e.g. lower alkyl esters
  • solvates e.g. hydrates
  • Particularly preferred medicaments for administration using aerosol formulations in accordance with the invention include anti-allergies, bronchodilators and anti- inflammatory steroids of use in the treatment of respiratory disorders such as asthma by inhalation therapy, for example cromoglycate (e.g. as the sodium salt), salbutamol (e.g. as the free base or as the sulphate salt), salmeterol. (e.g. as the xinafoate salt), terbutaline (e.g. as the sulphate salt), reproterol (e.g.
  • cromoglycate e.g. as the sodium salt
  • salbutamol e.g. as the free base or as the sulphate salt
  • salmeterol. e.g. as the xinafoate salt
  • terbutaline e.g. as the sulphate salt
  • reproterol e.g.
  • beclomethasone dipropionate as the hydrochloride salt
  • fluticasone propionate or (-)-4-amino-3,5-dichloro- ⁇ -[[[6-[2- (2-pyridinyl)-ethoxy]hexyl]amino]- methyl] benzenemethanol.
  • Salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof are especially preferred.
  • the aerosol formulations according to the invention may , if desired, contain a combination of two or more active ingredients.
  • Aerosol compositions containing two active ingredients are known, for example, for the treatment of respiratory disorders such as asthma.
  • the present invention further provides aerosol formulations in accordance with the invention which contain two or more particulate medicaments.
  • Medicaments may be selected from suitable combinations of the medicaments mentioned hereinbefore.
  • suitable combinations of bronchodilatory agents include ephedrine and theophylline, fenoterol and ipratropium, and isoetharine and phenylephrine aerosol formulations.
  • Preferred aerosol formulations in accordance with the invention comprise (a) an effective amount of a particulate bronchodilatory medicament (b) an effective amount of a particulate antiinflammatory, preferably a steroidal antiinflammatory medicament (c) a fluorocarbon or hydrogen - containing chlorofluorocarbon propellant and (d) up to 5% w/w based upon propellant of a. polar cosolvent.
  • Particularly preferred aerosol formulations contain bronchodilators such as salbutamol (e.g. as the free. base or as the sulphate salt), salmeterol (e.g.
  • aerosol formulations may contain a bronchodilator in combination with an antiallergic such as cromoglycate (e.g. the sodium salt).
  • cromoglycate e.g. the sodium salt.
  • the final aerosol formulation desirably contains 0.005-10% w/w, preferably 0.005-5% w/w, especially 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.
  • the propellants for use in the invention may be any fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof having a sufficient vapour pressure to render them effective as propellants.
  • the propellant will be a non-solvent for the medicament.
  • Suitable propellants include, • for example, C M hydrogen-containing chlorofluorocarbons such as CH j ClF, CC1F 2 CHC1F, CF 3 CHCIF, CHF,CC1F 2 , CHC1FCHF 2 , CF 3 CH 2 CI and CC1F 2 CH 3 ; C ⁇ hydrogen-containing fluorocarbons such as CHF 2 CHF,, CF 3 CH,F, CHF 2 CH 3 and CF-CHFCF,; and perfluorocarbons such as CF 3 CF 3 and CF 3 CF,CF 3 .
  • C M hydrogen-containing chlorofluorocarbons such as CH j ClF, CC1F 2 CHC1F, CF 3 CHCIF, CHF,CC1F 2 , CHC1FCHF 2 , CF 3 CH 2 CI and CC1F 2 CH 3
  • C ⁇ hydrogen-containing fluorocarbons such as CHF 2 CHF,, CF 3 CH,F, CHF 2 CH 3
  • mixtures of the fluorocarbons or hydrogen-containing chlorofluorocarbons may be mixtures of the above identified compounds or mixtures, preferably binary mixtures, with other fluorocarbons or hydrogen-containing chloro ⁇ fluorocarbons for example CHC1F-, CH ⁇ F-, and CF 3 CH 3 .
  • a single fluorocarbon or hydrogen-containing chlorofluorocarbon is employed as the propellant.
  • propellants are C, ⁇ hydrogen-containing fluorocarbons such as 1, 1,1,2- tetrafluoroethane (CF.CU ⁇ ) and 1,1,1,2,3,3,3-heptafluoro-n-propane (CF 3 CHFCF 3 ).
  • the formulations of the invention contain no components which may provoke the degradation of stratospheric ozone.
  • the formulations are substantially free of chlorofluorocarbons such as CCI 3 F, CC1-F-, and CF 3 CC1 3 .
  • the propellant may additionally contain a volatile adjuvant such as a saturated hydrocarbon for example propane, n-butane, isobutane, pentane and. isopentane or a dialkyl ether for example dimethyl ether.
  • a volatile adjuvant such as a saturated hydrocarbon for example propane, n-butane, isobutane, pentane and. isopentane or a dialkyl ether for example dimethyl ether.
  • up to 50% w/w of the propellant may comprise a volatile hydrocarbon, for example 1 to 30% w/w.
  • formulations which are substantially free of volatile adjuvants are preferred.
  • Polar cosolvents which may be incorporated into the formulations according to the present invention include (e.g. C- ⁇ aliphatic alcohols and polyols such as ethanol, isopropanol and propylene glycol and mixtures thereof. Preferably ethanol will be employed. In general only small quantities (e.g. 0.05 to 3.0% w/w) of polar cosolvent are required to improve the dispersion and the use of quantities in excess of 5% w/w may disadvantageously tend to dissolve the medicament. Formulations preferably contain less than 1% w/w, e.g. about 0.1% w/w of polar cosolvent. Polarity may be determined for example, by the method described in European Patent Application Publication No. 0327777.
  • a particularly preferred embodiment of the invention provides a pharmaceutical aerosol formulation consisting essentially of one or more particulate medicament, one or more fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and 0.01 to 5% w/w based upon propellant of a polar cosolvent.
  • the formulations of the invention may be prepared by dispersal of the medicament in the selected propellant in an appropriate container, e.g. with the aid of sonication. It may be preferred to add the cosolvent after the medicament and propellant have been combined in order to minimise any solubilising effects of the cosolvent and thereby enhance the dispersion.
  • the process is desirably carried out under anhydrous conditions to obviate any adverse effects of moisture on suspension stability.
  • the formulations according to the invention form weakly flocculated suspensions on standing but, surprisingly, these suspensions have been found to be easily redispersed by mild agitation to provide suspensions with excellent delivery characteristics suitable for use in pressurised inhalers, even after prolonged storage- Minimising and preferably avoiding the use of formulation excipients e.g. surfactants in the aerosol formulations according to the invention is also advantageous since the formulations may be - substantially taste and odour free, less irritant and less toxic than conventional formulations.
  • the chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art- Thus, for example, the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product. Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.
  • the particle size distribution of the aerosol formulations according to the invention is particularly spectacular and may be measured by conventional techniques, for example by cascade impaction or by the "Twin Impinger" analytical process.
  • Twin Impinger assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A” as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XNII C. Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated.
  • respirable fraction means the amount of active ingredient collected in the lower impingement chamber per actuation expressed as a percentage of the total amount of active ingredient delivered per actuation using the twin impinger method described above.
  • the formulations according to the invention have been found to have a respirable fraction of 20% or more by weight of the medicament, preferably 25 to 70%, for example 30 to 60%.
  • the medicament may be surface-modified prior to its dispersion in the propellant by treatment with a substantially non-polar liquid medium which is a non-solvent for the medicament.
  • a substantially non-polar liquid medium which is a non-solvent for the medicament.
  • an aerosol formulation comprising particulate, surface-modified medicament, as defined herein, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant.
  • surface-modified medicament is meant particles of medicament which have been surface-modified- by admixture with a • substantially non-polar non-solvent liquid, followed by removal of the liquid.
  • the substantially non-polar non-solvent liquid medium is conveniently an aliphatic hydrocarbon, e.g. a lower alkane, which is sufficiently volatile to permit its ready evaporation, e.g. at ambient temperature and pressure, after slurrying with the medicament.
  • aliphatic hydrocarbon e.g. a lower alkane
  • isopentane as liquid medium is particularly advantageous in this respect.
  • the medicament is desirably slurried with the liquid medium under anhydrous conditions to obviate any adverse effects of moisture on suspension stability.
  • the slurry may advantageously be sonicated to maximise the surface-modifying effect of the treatment.
  • the liquid may be removed by any convenient means for example by evaporation or by filtration followed by evaporation, provided that following treatment the medicament is substantially free of the liquid.
  • the formulations of the invention will be substantially free of the non-solvent non-polar liquid.
  • the formulations according to the invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations.
  • Canisters generally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve.
  • the metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve.
  • the gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene.
  • suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Nalois, France (e.g. DF10, DF30, DF60), Bespak pic, UK (e g. BK300, BK356) and 3M- ⁇ eotechnic Ltd, UK (e.g. SpraymiserTM).
  • a metering valve is crimped onto an aluminium can to form an empty canister.
  • the particulate medicament is added to a charge vessel and a mixture of the polar cosolvent and liquified propellant is pressure filled through the charge vessel into a manufacturing vessel.
  • the drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister.
  • the particulate medicament may be suspended in 50 - 90% w/w of the propellant before the cosolvent is added and then made up to weight with propellent before pressure filling into canisters.
  • each filled canister is check-weighed, coded with a batch number and packed into a tray for storage before release testing.
  • Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient.
  • Suitable channelling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator.
  • Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation or "puff 1 , for example in the range of 10 to 5000 microgram medicament per puff.
  • Administration of medicament may be indicated for the treatment of mild, moderate or severe acute or chronic symptoms or for prophylactic treatment. It will be appreciated that the precise dose administered will depend on the age and condition of the patient, the particular particulate medicament used and the frequency of administration and will ultimately be at the discretion of the attendant physician. When combinations of medicaments are employed the dose of each component of the combination will in general be that employed for each component when used alone. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time.
  • each valve actuation may deliver 25 microgram -salmeterol, 100 microgram salbutamol, 25, 50, 125 or 250 microgram fluticasone propionate or 50, 100,
  • each filled canister for use in a metered dose inhaler contains 100, 160 or 240 metered doses or puffs of medicament.
  • the filled canisters and metered dose inhalers described herein comprise further aspects of the present invention.
  • a still further aspect of the present invention comprises a method of treating respiratory disorders such as, for example, asthma, which comprises administration by inhalation of an effective amount of a formulation as herein described.
  • Example 1 Micronised salmeterol xinafoate (9.57mg) was weighed directly into an open aluminium can. 1,1, 1,2-Tetrafluoroethane (18.2g) was added from a vacuum flask together with ethanol (182mg) and a metering valve was crimped into place. The resulting aerosol contained 9.57mg salmeterol xinafoate (1.0% w/w ethanol) and delivered 25 microgram salmeterol per actuation.
  • Example 2 Micronised salmeterol xinafoate (9.57mg) was weighed directly into an open aluminium can. 1,1, 1,2-Tetrafluoroethane (18.2g) was added from a vacuum flask together with ethanol (182mg) and a metering valve was crimped into place. The resulting aerosol contained 9.57mg salmeterol xinafoate (1.0% w/w ethanol) and delivered 25 microgram salmeterol per
  • Micronised salmeterol xinafoate (9.57mg) was weighed directly into an open aluminium can. 1,1,1,2-Tetrafluoroethane (18.2g) was added from a vacuum flask together with ethanol (0.455g) and a metering valve was crimped into place. The resulting inhalers contained 9.57mg salmeterol xinafoate (2.5% w/w ethanol) and delivered 50 microgram salmeterol per actuation.
  • Micronised fluticasone propionate (66mg or 6.6mg) is weighed directly into each of 100 open aluminium cans and a metering valve is then crimped into place on each can. Ethanol (0.182g) and 1,1,1,2-tetrafluoroethane (18.2g) is then added to each canister under pressure, through the valve, and each filled canister shaken to disperse the drug.
  • the resulting inhalers contain 66 or 6.6mg fluticasone propionate (l%.w/w ethanol) and deliver 250 or 25 microgram fluticasone propionate. per actuation (Examples 3 and 4 respectively).
  • Micronised salbutamol (24mg or 48mg) is weighed directly into each of 3 open aluminium cans. 1,1,1,2-Tetrafluoroethane (18.2g) is added to each can from a vacuum flask together with ethanol (0.364g), and a metering valve is then crimped into place. Each filled canister is then shaken in an ultrasonic bath for 8 minutes- The resulting inhalers contain 24mg or 48mg salbutamol (2% w/w ethanol) and deliver 100 or 200 microgram salbutamol per actuation (Examples 5 and 6 respectively).
  • Isopentane (20ml) was added to micronised salmeterol xinafoate (0.5g) to form a slurry, which was sonicated for 3 minutes.
  • the resulting suspension was dried by evaporating the isopentane at ambient temperature to yield surface-modified salmeterol xinafoate.
  • Samples of this product (9.57mg) are weighed into aluminium aerosol cans, ethanol (91mg) and 1,1,1,2-tetrafluoroethane (18.2g - 99.95% w/w of total fill weight) is added and suitable metering valves are- crimped onto the cans.
  • the filled canisters are then each sonicated for 5 minutes.
  • the resulting aerosols contained salmeterol in an amount equivalent to 240 actuations at 25 microgram per actuation (0.5% w/w ethanol).
  • beclomethasone dipropionate monohydrate (68 mg) is weighed into a clean, dry plastic-coated glass bottle, 1,1,1,2-tetrafluoroethane (to 18.2g) is added from a vacuum flask together with ethanol (0.182g) and the bottle is quickly sealed with a metering valve.
  • the resulting aerosol dispensed 250 microgram beclomethasone dipropionate (as the monohydrate) per 75.8mg actuation (1% w/w ethanol).
  • Example 10 Micronised sodium cromoglycate (1.2g) is weighed directly into an aluminium can,
  • 1,1,1,2-tetrafluorethane (to 18.2g) added from a vacuum flask together with ethanol (455mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 5mg sodium cromoglycate per actuation (2.5% w/w ethanol).
  • Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can, 1,1,1,2-tetraflu ⁇ rethane (to 18.2g) added from a vacuum flask together with ethanol (91mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 250 microgram terbutaline sulphate per actuation (0.5% w/w ethanol).
  • Micronised reproterol hydrochloride 120mg is weighed directly into an aluminium can, 1,1,1,2-tetrafluorethane (to I8.2g) added from a vacuum flask together with ethanol (364mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 500 microgram reproterol hydrochloride per actuation (2% w/w ethanol).
  • Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can,
  • the aerosol delivers 250 microgram terbutaline sulphate per actuation
  • Micronised salmeterol xinafoate (9.57mg) is weighed directly into an aluminium can ' 0 and 1,1,1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (428mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 25 microgram salmeterol xinafoate per actuation (2% w/w ethanol).
  • Micronised fluticasone propionate (13.3mg) is weighed directly into an aluminium can, 1,1,1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (I07mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 50 microgram fluticasone propionate per actuation 0 (0.5% w/w ethanol).
  • Micronised salbutamol sulphate (31.7mg) is weighed directly into an aluminium can, 1,1, 1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (535mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 100 microgram salbutamol sulphate per actuation (2.5% w/w ethanol).
  • Example 17 Micronised. beclomethasone diproprionate (13.6mg) is weighed directly into an aluminium can, 1,1,1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (107mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 50 microgram beclomethasone diproprionate per actuation (0.5% w/w ethanol).
  • 1,1,1 ,2-Tetrafluoroethane * as free base or an equivalent weight of salt e.g. sulphate
  • micronised medicaments are weighed into aluminium cans,l,l, l,2-tetrafluoroethane (18.2g) is added from a vacuum flask, together with the ethanol, and metering valves are crimped into place.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thermistors And Varistors (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to a canister suitable for delivering a pharmaceutical aerosol formulation for inhalation therapy including a propellant which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation for inhalation therapy consisting essentially of a physiologically effective amount of particulate medicament, 1,1,1,2-tetrafluoroethane as propellant and up to 5% w/w based upon propellant of a polar co-solvent, which formulation is substantially free of surfactant.

Description

MEDICAMENTS
This invention relates to aerosol formulations of use for the administration of medicaments by inhalation.
The use of aerosols to administer medicaments has been known for several decades. Such aerosols generally comprise the medicament, one or more chlorofluorocarbon propellants and either a surfactant or a solvent, such as ethanol. The most commonly used aerosol propellants for medicaments have been propellant 1 1 (CC1,F) and/or propellant 1 14 (CF,C1CF,C1) with propellant 12 (CC12F,). However these propellants are now believed to provoke the degradation of stratospheric ozone and there is thus a need to provide aerosol formulations for medicaments which employ so called "ozonevfriendly" propellants.
A class of propellants which are believed to have minimal ozone-depleting effects in comparison to conventional chlorofluorocarbons comprise, fluorocarbons and hydrogen-containing chlorofluorocarbons, and a number of medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777, WO91/04011, WO91/11 173, WO91/11495 and WO91/14422. These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome the problems associated with the use of the new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared. The applications all propose the addition of one or more of adjuvants such as alcohols, alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids, polyethoxylates etc) and even conventional chlorofluorocarbon propellants in small amounts intended to minimise potential ozone damage.
Thus, for example EP 0372777 requires the use of 1, 1, 1,2-tetrafluoroethane in combination with both a cosolvent having greater polarity than 1, 1, 1,2-tetrafluoroethane (e.g. an alcohol or a lower alkane) and a surfactant in order to achieve a stable formulation of.a medicament powder. In particular it. is noted in the specification at page 3, line 7 that "it has been found that the use of propellant 134a (1, 1, 1,2- tetrafluoroethane) and drug as a binary mixture or in combination with a conventional surfactant such as sorbitan trioleate does not provide formulations having suitable properties for use with pressurised inhalers". Surfactants are generally recognised by those skilled in the art to be essential components of aerosol formulations, required not only to reduce aggregation of the medicament but also to lubricate the valve employed, thereby ensuring consistent reproducibilϊty of valve actuation and accuracy of dose dispensed. Whilst WO91/11173, WO91/11495 and WO91/14422 are concerned .with formulations comprising an admixture of drug and surfactant, WO91/04011 discloses medicinal aerosol formulations in which the particulate medicaments are pre-coated with -surfactant prior to dispersal in 1,1,1,2-tetrafluoroethane.
We have now surprisingly found that, in contradistinction to these teachings, it is in fact possible to obtain satisfactory dispersions of medicaments in fluorocarbon or hydrogen-containing chlorofluorocarbon propellants such as 1,1,1,2-tetrafluoroethane without recourse to the use of any surfactant in the composition, or the necessity to pre-treat the medicament prior to dispersal in the propellant.
There is thus provided in one aspect of the invention a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon • or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon * propellant of a polar cosolvent, which formulation is substantially free of surfactant. By "substantially free of surfactant" is meant formulations which contain no significant amounts of surfactant, for example less than 0.0001% by weight of the medicament. .
The particle size of the particulate (e.g. micronised) medicament should be such as to permit inhalation of substantially all of the medicament into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and preferably in the range 1-10 microns, e.g. 1-5 microns.
Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant. Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, - dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; anti-infectives, e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone; antitussives, e.g. noscapine; bronchodilators, e.g. ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, isoetharine, tulobuterol, orciprenaline, or (-)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzene- methanol; diuretics, e.g. amiloride; anticholinergics e.g. ipratropium, atropine or oxitropium; hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, e.g. insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.
Particularly preferred medicaments for administration using aerosol formulations in accordance with the invention include anti-allergies, bronchodilators and anti- inflammatory steroids of use in the treatment of respiratory disorders such as asthma by inhalation therapy, for example cromoglycate (e.g. as the sodium salt), salbutamol (e.g. as the free base or as the sulphate salt), salmeterol. (e.g. as the xinafoate salt), terbutaline (e.g. as the sulphate salt), reproterol (e.g. as the hydrochloride salt), beclomethasone dipropionate, fluticasone propionate or (-)-4-amino-3,5-dichloro-α-[[[6-[2- (2-pyridinyl)-ethoxy]hexyl]amino]- methyl] benzenemethanol. Salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof are especially preferred.
It will be appreciated by those skilled in the art that the aerosol formulations according to the invention may , if desired, contain a combination of two or more active ingredients. Aerosol compositions containing two active ingredients (in a conventional propellant system) are known, for example, for the treatment of respiratory disorders such as asthma. Accordingly the present invention further provides aerosol formulations in accordance with the invention which contain two or more particulate medicaments. Medicaments may be selected from suitable combinations of the medicaments mentioned hereinbefore. Thus, suitable combinations of bronchodilatory agents include ephedrine and theophylline, fenoterol and ipratropium, and isoetharine and phenylephrine aerosol formulations.
Preferred aerosol formulations in accordance with the invention comprise (a) an effective amount of a particulate bronchodilatory medicament (b) an effective amount of a particulate antiinflammatory, preferably a steroidal antiinflammatory medicament (c) a fluorocarbon or hydrogen - containing chlorofluorocarbon propellant and (d) up to 5% w/w based upon propellant of a. polar cosolvent. Particularly preferred aerosol formulations contain bronchodilators such as salbutamol (e.g. as the free. base or as the sulphate salt), salmeterol (e.g. as the xinafoate salt) or isoprenaline in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g. the diproprionate)or a fluticasone ester (e.g. the propionate). Alternatively aerosol formulations may contain a bronchodilator in combination with an antiallergic such as cromoglycate (e.g. the sodium salt). Combinations of isoprenaline and sodium cromoglycate, salmeterol and fluticasone propionate,- or salbutamol and beclomethasone dipropionate are especially preferred.
The final aerosol formulation desirably contains 0.005-10% w/w, preferably 0.005-5% w/w, especially 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.
The propellants for use in the invention may be any fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof having a sufficient vapour pressure to render them effective as propellants. Preferably the propellant will be a non-solvent for the medicament. Suitable propellants include, • for example, CMhydrogen-containing chlorofluorocarbons such as CHjClF, CC1F2CHC1F, CF3CHCIF, CHF,CC1F2, CHC1FCHF2, CF3CH2CI and CC1F2CH3; C^hydrogen-containing fluorocarbons such as CHF2CHF,, CF3CH,F, CHF2CH3 and CF-CHFCF,; and perfluorocarbons such as CF3CF3 and CF3CF,CF3.
Where mixtures of the fluorocarbons or hydrogen-containing chlorofluorocarbons are employed they may be mixtures of the above identified compounds or mixtures, preferably binary mixtures, with other fluorocarbons or hydrogen-containing chloro¬ fluorocarbons for example CHC1F-, CH^F-, and CF3CH3. Preferably a single fluorocarbon or hydrogen-containing chlorofluorocarbon is employed as the propellant. Particularly preferred as propellants are C, ^hydrogen-containing fluorocarbons such as 1, 1,1,2- tetrafluoroethane (CF.CU^) and 1,1,1,2,3,3,3-heptafluoro-n-propane (CF3CHFCF3). It is desirable that the formulations of the invention contain no components which may provoke the degradation of stratospheric ozone. In particular it is desirable that the formulations are substantially free of chlorofluorocarbons such as CCI3F, CC1-F-, and CF3CC13.
The propellant may additionally contain a volatile adjuvant such as a saturated hydrocarbon for example propane, n-butane, isobutane, pentane and. isopentane or a dialkyl ether for example dimethyl ether. In general, up to 50% w/w of the propellant may comprise a volatile hydrocarbon, for example 1 to 30% w/w. However, formulations which are substantially free of volatile adjuvants are preferred.
Polar cosolvents which may be incorporated into the formulations according to the present invention include (e.g. C-^aliphatic alcohols and polyols such as ethanol, isopropanol and propylene glycol and mixtures thereof. Preferably ethanol will be employed. In general only small quantities (e.g. 0.05 to 3.0% w/w) of polar cosolvent are required to improve the dispersion and the use of quantities in excess of 5% w/w may disadvantageously tend to dissolve the medicament. Formulations preferably contain less than 1% w/w, e.g. about 0.1% w/w of polar cosolvent. Polarity may be determined for example, by the method described in European Patent Application Publication No. 0327777.
A particularly preferred embodiment of the invention provides a pharmaceutical aerosol formulation consisting essentially of one or more particulate medicament, one or more fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and 0.01 to 5% w/w based upon propellant of a polar cosolvent.
The formulations of the invention may be prepared by dispersal of the medicament in the selected propellant in an appropriate container, e.g. with the aid of sonication. It may be preferred to add the cosolvent after the medicament and propellant have been combined in order to minimise any solubilising effects of the cosolvent and thereby enhance the dispersion. The process is desirably carried out under anhydrous conditions to obviate any adverse effects of moisture on suspension stability.
. The formulations according to the invention form weakly flocculated suspensions on standing but, surprisingly, these suspensions have been found to be easily redispersed by mild agitation to provide suspensions with excellent delivery characteristics suitable for use in pressurised inhalers, even after prolonged storage- Minimising and preferably avoiding the use of formulation excipients e.g. surfactants in the aerosol formulations according to the invention is also advantageous since the formulations may be - substantially taste and odour free, less irritant and less toxic than conventional formulations.
The chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art- Thus, for example, the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product. Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis. The particle size distribution of the aerosol formulations according to the invention is particularly impressive and may be measured by conventional techniques, for example by cascade impaction or by the "Twin Impinger" analytical process. As used herein reference to the "Twin Impinger" assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A" as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XNII C. Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated. As used herein reference to "respirable fraction" means the amount of active ingredient collected in the lower impingement chamber per actuation expressed as a percentage of the total amount of active ingredient delivered per actuation using the twin impinger method described above. The formulations according to the invention have been found to have a respirable fraction of 20% or more by weight of the medicament, preferably 25 to 70%, for example 30 to 60%.
Optionally, the medicament may be surface-modified prior to its dispersion in the propellant by treatment with a substantially non-polar liquid medium which is a non-solvent for the medicament. There is thus provided in a further aspect of the invention an aerosol formulation comprising particulate, surface-modified medicament, as defined herein, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant. By "surface-modified medicament" is meant particles of medicament which have been surface-modified- by admixture with a •substantially non-polar non-solvent liquid, followed by removal of the liquid. The substantially non-polar non-solvent liquid medium is conveniently an aliphatic hydrocarbon, e.g. a lower alkane, which is sufficiently volatile to permit its ready evaporation, e.g. at ambient temperature and pressure, after slurrying with the medicament. The use of isopentane as liquid medium is particularly advantageous in this respect.
The medicament is desirably slurried with the liquid medium under anhydrous conditions to obviate any adverse effects of moisture on suspension stability. The slurry may advantageously be sonicated to maximise the surface-modifying effect of the treatment. The liquid may be removed by any convenient means for example by evaporation or by filtration followed by evaporation, provided that following treatment the medicament is substantially free of the liquid. The formulations of the invention will be substantially free of the non-solvent non-polar liquid.
The formulations according to the invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations. Canisters generally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve. The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Nalois, France (e.g. DF10, DF30, DF60), Bespak pic, UK (e g. BK300, BK356) and 3M-Νeotechnic Ltd, UK (e.g. Spraymiser™).
Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large scale batches for the commercial production of filled canisters. Thus, for example, in one bulk manufacturing method a metering valve is crimped onto an aluminium can to form an empty canister. The particulate medicament is added to a charge vessel and a mixture of the polar cosolvent and liquified propellant is pressure filled through the charge vessel into a manufacturing vessel. The drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister. Alternatively, where the drug is particularly soluble in the polar cosolvent, the particulate medicament may be suspended in 50 - 90% w/w of the propellant before the cosolvent is added and then made up to weight with propellent before pressure filling into canisters. Typically, in batches prepared for pharmaceutical use, each filled canister is check-weighed, coded with a batch number and packed into a tray for storage before release testing. Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient. Suitable channelling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator. Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation or "puff1, for example in the range of 10 to 5000 microgram medicament per puff.
Administration of medicament may be indicated for the treatment of mild, moderate or severe acute or chronic symptoms or for prophylactic treatment. It will be appreciated that the precise dose administered will depend on the age and condition of the patient, the particular particulate medicament used and the frequency of administration and will ultimately be at the discretion of the attendant physician. When combinations of medicaments are employed the dose of each component of the combination will in general be that employed for each component when used alone. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time.
Thus, for example, each valve actuation may deliver 25 microgram -salmeterol, 100 microgram salbutamol, 25, 50, 125 or 250 microgram fluticasone propionate or 50, 100,
200 or 250 microgram beclomethasone dipropionate. Typically each filled canister for use in a metered dose inhaler contains 100, 160 or 240 metered doses or puffs of medicament.
The filled canisters and metered dose inhalers described herein comprise further aspects of the present invention.
A still further aspect of the present invention comprises a method of treating respiratory disorders such as, for example, asthma, which comprises administration by inhalation of an effective amount of a formulation as herein described.
The following non-limitative Examples serve to illustrate the invention.
Example 1 Micronised salmeterol xinafoate (9.57mg) was weighed directly into an open aluminium can. 1,1, 1,2-Tetrafluoroethane (18.2g) was added from a vacuum flask together with ethanol (182mg) and a metering valve was crimped into place. The resulting aerosol contained 9.57mg salmeterol xinafoate (1.0% w/w ethanol) and delivered 25 microgram salmeterol per actuation. Example 2
Micronised salmeterol xinafoate (9.57mg) was weighed directly into an open aluminium can. 1,1,1,2-Tetrafluoroethane (18.2g) was added from a vacuum flask together with ethanol (0.455g) and a metering valve was crimped into place. The resulting inhalers contained 9.57mg salmeterol xinafoate (2.5% w/w ethanol) and delivered 50 microgram salmeterol per actuation.
Examples 3 and 4
Micronised fluticasone propionate (66mg or 6.6mg) is weighed directly into each of 100 open aluminium cans and a metering valve is then crimped into place on each can. Ethanol (0.182g) and 1,1,1,2-tetrafluoroethane (18.2g) is then added to each canister under pressure, through the valve, and each filled canister shaken to disperse the drug. The resulting inhalers contain 66 or 6.6mg fluticasone propionate (l%.w/w ethanol) and deliver 250 or 25 microgram fluticasone propionate. per actuation (Examples 3 and 4 respectively).
Examples 5 and 6
Micronised salbutamol (24mg or 48mg) is weighed directly into each of 3 open aluminium cans. 1,1,1,2-Tetrafluoroethane (18.2g) is added to each can from a vacuum flask together with ethanol (0.364g), and a metering valve is then crimped into place. Each filled canister is then shaken in an ultrasonic bath for 8 minutes- The resulting inhalers contain 24mg or 48mg salbutamol (2% w/w ethanol) and deliver 100 or 200 microgram salbutamol per actuation (Examples 5 and 6 respectively).
Example 7
Micronised salbutamol sulphate (15mg) was weighed directly into an open aluminium can. 1,1,1,2-Tetrafluoroethaπe (18.2g) was added from a vacuum flask together with ethanol (O.I82g) and a metering valve was then crimped into place. The filled canister was then shaken in an ultrasonic bath for 5 minutes. The resulting inhaler contained 15mg salbutamol sulphate (1% w/w ethanol). Example 8
Isopentane (20ml) was added to micronised salmeterol xinafoate (0.5g) to form a slurry, which was sonicated for 3 minutes. The resulting suspension was dried by evaporating the isopentane at ambient temperature to yield surface-modified salmeterol xinafoate. Samples of this product (9.57mg) are weighed into aluminium aerosol cans, ethanol (91mg) and 1,1,1,2-tetrafluoroethane (18.2g - 99.95% w/w of total fill weight) is added and suitable metering valves are- crimped onto the cans. The filled canisters are then each sonicated for 5 minutes. The resulting aerosols contained salmeterol in an amount equivalent to 240 actuations at 25 microgram per actuation (0.5% w/w ethanol).
Example 9
-Micronised beclomethasone dipropionate monohydrate (68 mg) is weighed into a clean, dry plastic-coated glass bottle, 1,1,1,2-tetrafluoroethane (to 18.2g) is added from a vacuum flask together with ethanol (0.182g) and the bottle is quickly sealed with a metering valve. The resulting aerosol dispensed 250 microgram beclomethasone dipropionate (as the monohydrate) per 75.8mg actuation (1% w/w ethanol).
Example 10 Micronised sodium cromoglycate (1.2g) is weighed directly into an aluminium can,
1,1,1,2-tetrafluorethane (to 18.2g) added from a vacuum flask together with ethanol (455mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 5mg sodium cromoglycate per actuation (2.5% w/w ethanol).
Example 1 1
Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can, 1,1,1,2-tetrafluόrethane (to 18.2g) added from a vacuum flask together with ethanol (91mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 250 microgram terbutaline sulphate per actuation (0.5% w/w ethanol).
Example 12
Micronised reproterol hydrochloride (120mg) is weighed directly into an aluminium can, 1,1,1,2-tetrafluorethane (to I8.2g) added from a vacuum flask together with ethanol (364mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 500 microgram reproterol hydrochloride per actuation (2% w/w ethanol).
10
Example 13
Micronised terbutaline sulphate (60mg) is weighed directly into an aluminium can,
1,1,1,2,3,3,3-heptafluoro-n-propane (to -21.4g) added from a vacuum flask together with ethanol (214mg). A metering valve is crimped into place and the filled canister sonicated
15. for five minutes. The aerosol delivers 250 microgram terbutaline sulphate per actuation
(1% w/w ethanol).
Example 14
Micronised salmeterol xinafoate (9.57mg) is weighed directly into an aluminium can ' 0 and 1,1,1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (428mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 25 microgram salmeterol xinafoate per actuation (2% w/w ethanol).
5 Example 15
Micronised fluticasone propionate (13.3mg) is weighed directly into an aluminium can, 1,1,1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (I07mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 50 microgram fluticasone propionate per actuation 0 (0.5% w/w ethanol). Example 16
Micronised salbutamol sulphate (31.7mg) is weighed directly into an aluminium can, 1,1, 1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (535mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 100 microgram salbutamol sulphate per actuation (2.5% w/w ethanol).
Example 17 Micronised. beclomethasone diproprionate (13.6mg) is weighed directly into an aluminium can, 1,1,1,2,3,3,3-heptafluoro-n-propane (to 21.4g) added from a vacuum flask together with ethanol (107mg). A metering valve is crimped into place and the filled canister sonicated for five minutes. The aerosol delivers 50 microgram beclomethasone diproprionate per actuation (0.5% w/w ethanol).
Example 18
Salmeterol xinafoate Fluticasone propionate Ethanol
1,1, 1 ,2-Tetrafluoroethane
Example 19
Salmeterol xinafoate
Fluticasone propionate Ethanol 1,1, 1 ,2-Tetrafluoroethane
Example 20 Per Inhaler % w/w Per Actuation
Salmeterol xinafoate 0.048 36.25 microgram
Fluticasone propionate 0.066 50 microgram
Ethanol 0.5 0.38mg
1, 1,1,2-Tetrafluoroethane to 100 to 75.8mg
Example 21
Per Inhaler % w/w Per Actuation
Salmeterol xinafoate 0.048 36.25 microgram
Fluticasone propionate 0.165 125 microgram
Ethanol 1.0 0.76mg
1,1,1 ,2-Tetrafluoroethane to 100 to 75.8mg
Example 22
Salbutamol * Fluticasone propionate Ethanol
1,1, 1,2-Tetrafluoroethane * as free base or an equivalent weight of salt e.g. sulphate
Example 23
Salbutamol * Fluticasone propionate
Ethanol
1,1,1 ,2-Tetrafluoroethane * as free base or an equivalent weight of salt e.g. sulphate
Example 24
Salmeterol xinafoate
Fluticasone propionate
Ethanol
1,1,1 ,2-Tetrafluoroethane
Exam le 26
as free base or an equivalent weight of salt e.g. sulphate
Exam le 27
as free base or an equivalent weight of salt e.g. sulphate In Examples 18 to 27 micronised medicaments are weighed into aluminium cans,l,l, l,2-tetrafluoroethane (18.2g) is added from a vacuum flask, together with the ethanol, and metering valves are crimped into place.

Claims

Claims
1. A pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w
-> based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant.
2. A pharmaceutical aerosol formulation consisting essentially of one or more particulate medicament, one or more fluorocarbon or hydrogen-containing
*" chlorofluorocarbon propellant and 0.01 to 5% w/w based upon propellant of a polar cosolvent.
3. A formulation as claimed in Claim 1 or Claim 2 wherein said medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid. 15
4. A formulation as claimed in any one of Claims 1 to 3 wherein said medicament is selected from salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof.
0 5. A formulation as claimed in any one of Claims 1 to 4 which contains two or more particulate medicaments.
6. A formulation as claimed in any one of Claims 1 to 5 which comprises a particulate bronchodilatory medicament and a particulate anti-inflammatory medicament. 5
7. A formulation as claimed in any one of Claims 1 to 6 which comprises salmeterol or a physiologically acceptable salt thereof in combination with fluticasone propionate.
0
8. A formulation as claimed in any one of Claims 1 to 7 which comprises salmeterol xinafoate in combination with fluticasone propionate.
9. A formulation as claimed in any one of Claims 1 to 8 wherein the propellant comprises 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane.
10. A formulation as claimed in any one of Claims 1 to 9 wherein the polar cosolvent is ethanol.
11. A formulation as claimed in any one of Claims 1 to 10 wherein the medicament is present in an amount of 0.005 to 10% w/w based on the total weight of the formulation.
12- A formulation as claimed in any one of Claims Λ to 11 which has. a respirable fraction of 20% or more by weight of the medicament.
13. A formulation as claimed in any one of Claims 1 to 12 wherein said particulate medicament is surface-modified.
1.4. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant.
15. A metered dose inhaler which comprises a canister as claimed in Claim 14 fitted into a suitable channelling device.
16. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation which I9 comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant.
EP92924669A 1991-12-12 1992-12-04 Pharmaceutical aerosol formulation Revoked EP0616525B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9126444 1991-12-12
GB919126444A GB9126444D0 (en) 1991-12-12 1991-12-12 Medicaments
GB9202522 1992-02-06
GB929202522A GB9202522D0 (en) 1992-02-06 1992-02-06 Medicaments
PCT/EP1992/002810 WO1993011745A1 (en) 1991-12-12 1992-12-04 Medicaments

Publications (2)

Publication Number Publication Date
EP0616525A1 true EP0616525A1 (en) 1994-09-28
EP0616525B1 EP0616525B1 (en) 1995-09-27

Family

ID=26299998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92924669A Revoked EP0616525B1 (en) 1991-12-12 1992-12-04 Pharmaceutical aerosol formulation

Country Status (16)

Country Link
US (1) US5817293A (en)
EP (1) EP0616525B1 (en)
JP (1) JP3280974B2 (en)
AT (1) ATE128350T1 (en)
AU (1) AU663906B2 (en)
CA (1) CA2125665C (en)
CY (1) CY2008A (en)
DE (1) DE69205177T2 (en)
DK (1) DK0616525T3 (en)
ES (1) ES2079210T3 (en)
GR (1) GR3018168T3 (en)
HK (1) HK79097A (en)
MX (1) MX9207200A (en)
NZ (1) NZ246046A (en)
TW (1) TW229159B (en)
WO (1) WO1993011745A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776432A (en) * 1990-10-18 1998-07-07 Minnesota Mining And Manufacturing Company Beclomethasone solution aerosol formulations
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
AU721920B2 (en) * 1996-08-01 2000-07-20 Norton Healthcare Limited Aerosol formulations
US6352684B1 (en) 1988-12-06 2002-03-05 Riker Laboratories Inc. CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US8759369B2 (en) 2007-07-09 2014-06-24 Norton Healthcare Ltd. Inhalable solid amorphous particles comprising tiotropium bromide and a co-solid
WO2016061445A1 (en) 2014-10-16 2016-04-21 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable formulation
US9526790B2 (en) 2007-06-27 2016-12-27 Generics [Uk] Limited Pharmaceutical aerosol compositions comprising fluticasone
US9655969B2 (en) 2011-12-19 2017-05-23 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
US9730890B2 (en) 2003-07-10 2017-08-15 Mylan Pharmaceuticals, Inc. Bronchodilating beta-agonist compositions and methods
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
ATE171865T1 (en) 1991-12-12 1998-10-15 Glaxo Group Ltd DRUG
IL104068A (en) † 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
DE69218455T2 (en) 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. AEROSOL COMPOSITIONS FOR MEDICAL SUSPENSIONS
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
PE44995A1 (en) * 1994-01-27 1995-12-18 Schering Corp MOMETASONE FUROATE FOR THE TREATMENT OF LUNG DISEASES AND RESPIRATORY TRACT
AU709783B2 (en) * 1994-03-14 1999-09-09 Abbott Laboratories Aerosol drug formulations containing vitamin E
BG61430B1 (en) * 1994-03-23 1997-08-29 Иван ХРИСТОВ Antiasthma medicament
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
EP0820323B1 (en) * 1995-04-14 2003-09-24 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
ES2276736T3 (en) * 1995-04-14 2007-07-01 Smithkline Beecham Corporation DOSE METER INHALER FOR FLUCTICASONE PROPIONATE.
SI0820279T1 (en) * 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
AU752682B2 (en) * 1995-04-14 2002-09-26 Smithkline Beecham Corporation Metered dose inhaler for salmeterol
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6235725B1 (en) 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
GB2388843B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd A metered dose inhaler containing a pharmaceutical formulation of fluticasone propionate
EP1143930B8 (en) 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
MXPA04005865A (en) 2001-12-19 2004-09-13 Nektar Therapeutics Pulmonary delivery of aminoglycosides.
US20040241103A1 (en) * 2002-09-10 2004-12-02 3M Innovative Properties Company Pharmaceutical aerosol compositions
US20060062812A1 (en) * 2003-03-11 2006-03-23 Calvin Ross Novel compositions
US6907690B1 (en) * 2003-04-25 2005-06-21 Jimmie L. Stallings Environmentally friendly insect eradication method and apparatus
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
WO2004110460A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
ES2691033T3 (en) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Therapeutic administration method of DHE to activate rapid migraine relief while minimizing the profile of side effects
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases
US20130008540A1 (en) 2011-07-08 2013-01-10 S.C. Johnson, Son. & Inc. Insert for dispensing a compressed gas product, system with such an insert, and method of dispensing a compressed gas product
WO2016018892A1 (en) 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (en) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (en) * 1957-01-31 1957-04-11
NL289785A (en) * 1962-11-29
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3895111A (en) * 1973-06-27 1975-07-15 American Cyanamid Co Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IL51314A (en) * 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
NL7708731A (en) * 1976-08-13 1978-02-15 Montedison Spa PROCESS FOR THE PREPARATION OF NEW DRIVER COMPOSITIONS FOR AEROSOLS.
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
DE4003270A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS
WO1991014422A1 (en) * 1990-03-23 1991-10-03 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
NZ238749A (en) * 1990-06-28 1993-07-27 Glaxo Inc Aerosol inhalation drug formulations with 1,1,1,2-tetrafluoroethane as propellant and a perfluorinated surfactant
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
DE69105212T2 (en) * 1990-10-18 1995-03-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. AEROSOL PREPARATION CONTAINING BECLOMETASON 17.21 DIPROPIONATE.
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
NZ243061A (en) * 1991-06-10 1993-09-27 Schering Corp Aerosol containing a medicament and 1,1,1,2,3,3,3-heptafluoropropane
US6503482B1 (en) * 1991-06-10 2003-01-07 Schering Corporation Non-chlorofluorocarbon aerosol formulations
ATE171865T1 (en) * 1991-12-12 1998-10-15 Glaxo Group Ltd DRUG
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
DE69218455T2 (en) * 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. AEROSOL COMPOSITIONS FOR MEDICAL SUSPENSIONS
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9311745A1 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352684B1 (en) 1988-12-06 2002-03-05 Riker Laboratories Inc. CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US5776432A (en) * 1990-10-18 1998-07-07 Minnesota Mining And Manufacturing Company Beclomethasone solution aerosol formulations
US6346232B1 (en) 1990-10-18 2002-02-12 3M Innovative Properties Company Method of forming conductive lines
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
AU721920B2 (en) * 1996-08-01 2000-07-20 Norton Healthcare Limited Aerosol formulations
US7566445B1 (en) 1996-08-01 2009-07-28 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US8834849B2 (en) 1996-08-01 2014-09-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US9650203B2 (en) 1996-08-01 2017-05-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US9730890B2 (en) 2003-07-10 2017-08-15 Mylan Pharmaceuticals, Inc. Bronchodilating beta-agonist compositions and methods
US9526790B2 (en) 2007-06-27 2016-12-27 Generics [Uk] Limited Pharmaceutical aerosol compositions comprising fluticasone
US8759369B2 (en) 2007-07-09 2014-06-24 Norton Healthcare Ltd. Inhalable solid amorphous particles comprising tiotropium bromide and a co-solid
US9655969B2 (en) 2011-12-19 2017-05-23 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2016061445A1 (en) 2014-10-16 2016-04-21 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable formulation

Also Published As

Publication number Publication date
CY2008A (en) 1998-02-20
HK79097A (en) 1997-06-20
TW229159B (en) 1994-09-01
CA2125665A1 (en) 1993-06-24
CA2125665C (en) 2001-06-12
DE69205177T2 (en) 1996-03-21
ES2079210T3 (en) 1996-01-01
AU663906C (en) 1993-07-19
DE69205177D1 (en) 1995-11-02
US5817293A (en) 1998-10-06
NZ246046A (en) 1995-12-21
ATE128350T1 (en) 1995-10-15
DK0616525T3 (en) 1996-01-08
MX9207200A (en) 1993-07-01
AU663906B2 (en) 1995-10-26
GR3018168T3 (en) 1996-02-29
JP3280974B2 (en) 2002-05-13
JPH07501811A (en) 1995-02-23
WO1993011745A1 (en) 1993-06-24
AU3085292A (en) 1993-07-19
EP0616525B1 (en) 1995-09-27

Similar Documents

Publication Publication Date Title
AU663906C (en) Medicaments
US5736124A (en) Aerosol formulations containing P134a and particulate medicament
AU663904C (en) Medicaments
US5922306A (en) Aerosol formulations containing P134a and particulate medicament
US5744123A (en) Aerosol formulations containing P134a and particulate medicaments
US5653962A (en) Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) Aerosol formulations containing P134a and salbutamol
US6221339B1 (en) Medicaments
US5658549A (en) Aerosol formulations containing propellant 134a and fluticasone propionate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940513

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19941108

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 128350

Country of ref document: AT

Date of ref document: 19951015

Kind code of ref document: T

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 65451

REF Corresponds to:

Ref document number: 69205177

Country of ref document: DE

Date of ref document: 19951102

ITF It: translation for a ep patent filed
ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Effective date: 19951227

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2079210

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3018168

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

26 Opposition filed

Opponent name: CIBA-GEIGY AG

Effective date: 19960625

Opponent name: JAGO PHARMA AG

Effective date: 19960625

Opponent name: ADIR ET COMPAGNIE

Effective date: 19960624

26 Opposition filed

Opponent name: RHOHE-POULENC RORER LIMITED

Effective date: 19960627

Opponent name: CIBA-GEIGY AG

Effective date: 19960625

Opponent name: JAGO PHARMA AG

Effective date: 19960625

Opponent name: ADIR ET COMPAGNIE

Effective date: 19960624

NLR1 Nl: opposition has been filed with the epo

Opponent name: RHOHE-POULENC RORER LIMITED

Opponent name: CIBA-GEIGY AG

Opponent name: JAGO PHARMA AG

Opponent name: ADIR ET COMPAGNIE

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

R26 Opposition filed (corrected)

Opponent name: ADIR ET COMPAGNIE * 960625 JAGO PHARMA AG * 960625

Effective date: 19960624

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

NLR1 Nl: opposition has been filed with the epo

Opponent name: RHOHE-POULENC RORER LIMITED

Opponent name: NOVARTIS AG PATENT AND TRADEMARK DEPT.

Opponent name: JAGO PHARMA AG

Opponent name: ADIR ET COMPAGNIE

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

RDAH Patent revoked

Free format text: ORIGINAL CODE: EPIDOS REVO

APAC Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPO

APAE Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOS REFNO

APAC Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPO

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: ADIR ET COMPAGNIE * 19960625 SKYEPHARMA AG * 19960

Effective date: 19960624

NLR1 Nl: opposition has been filed with the epo

Opponent name: RHONE-POULENC RORER LIMITED

Opponent name: SKYEPHARMA AG

Opponent name: ADIR ET COMPAGNIE

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: ADIR ET COMPAGNIE * 19960625 SKYEPHARMA AG * 19960

Effective date: 19960624

NLR1 Nl: opposition has been filed with the epo

Opponent name: RHONE-POULENC RORER LIMITED

Opponent name: SKYEPHARMA AG

Opponent name: ADIR ET COMPAGNIE

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

R26 Opposition filed (corrected)

Opponent name: LES LABORATOIRES SERVIER * 19960625 SKYEPHARMA AG

Effective date: 19960624

NLR1 Nl: opposition has been filed with the epo

Opponent name: RHONE-POULENC RORER LIMITED

Opponent name: SKYEPHARMA AG

Opponent name: LES LABORATOIRES SERVIER

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20021205

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20021210

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20021211

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20021217

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20030218

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20031014

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20031029

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20031105

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20031106

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20031110

Year of fee payment: 12

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20031201

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20031202

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20031212

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 20031002

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Free format text: 20031002

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20040226

Year of fee payment: 12

NLR2 Nl: decision of opposition

Effective date: 20031002

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO